Abstract
BACKGROUND Risk factors for Parkinson’s disease (PD) can be more or less relevant to a population due to population-specific genetic architecture, local lifestyle habits, and environmental exposures. Therefore, it is essential to study PD at a local, regional, and continental scale in order to increase the knowledge on disease etiology.
OBJECTIVE We aimed to investigate the contribution of genetic and environmental factors to PD in a new Swedish case-control cohort.
METHODS PD patients (n=929) and matched population-based controls (n=935) from the southernmost county in Sweden were included in the cohort. Information on environmental exposures was obtained using questionnaires at inclusion. Genetic analyses included a genome-wide association study (GWAS), haplotype assessment, and a risk profile analysis using cumulative genetic risk scores.
RESULTS The cohort is a representative PD case-control cohort (64% men, mean age at diagnosis = 67 years, median Hoehn and Yahr score = 2.0), in which previously reported associations between PD and environmental factors, such as tobacco, could be confirmed. We describe the first GWAS of PD solely composed of PD patients from Sweden, and confirm associations to well-established risk alleles in SNCA. In addition, we identified a potential novel, population-specific PD risk variant in the PLPP4 locus (rs12771445) along with a risk haplotype in the region.
CONCLUSIONS This work provides an in-depth description of a new PD case-control cohort from southern Sweden in which we identified a potential novel PD risk locus, PLPP4. Replication studies are needed to determine whether the PLPP4 locus is associated with PD in Sweden, and on a global scale.
Competing Interest Statement
KB, MS, SBC, CB, AP, PO and HW have no conflicts of interest to report. OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau, and Roche.
Funding Statement
This research was supported by MultiPark - a Strategic Research Area at Lund University and by grants from the Swedish Research Council (VR), Ake Wiberg's foundation, Parkinsonfonden, Ahlen foundation, Lindhes advokatbyra, and Sigurd & Elsa Golje's memorial foundation (KB/MS). This work was also supported in part by the Intramural Research Program of the National Institute on Aging (NIA) (SBC/CB), part of the National Institutes of Health, Department of Health and Human Services. AP receives research support from the Swedish government (ALF), Region Skane, Skane University Hospital, Bundy Academy, Hans Gabriel and Alice Trolle Wachtmeister Stiftelse for Medicinsk Forskning, The Swedish Parkinson Association, SCA network, all in Sweden, and receives reimbursement from Elsevier Ltd. PO has received research support from The Swedish National Government and County Councils, Skane University Hospital Foundations and Donations, Region Skane, Parkinsonfonden, Swedish Parkinson Academy and Ahlens Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical permission for the MultiPark's biobank sample collection (MPBC) was approved by the regional ethics review board of Lund (2013/509). All participants recruited to MPBC gave informed written consent at study enrollment.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code for all analyses and GWAS summary statistics will be available online. MultiPark's biobank sample collection (MPBC) is a resource at the Medical Faculty at Lund University which researchers can apply to for use for research within Parkinson's disease
https://github.com/KajBro/MPBC
https://drive.google.com/file/d/1kQJTIZAk1JNw-Dlu6ZHS95I2qw78Vuu_/view?usp=sharing
https://www.multipark.lu.se/infrastructures/biobank-platform
